Business
Teva Canada Announces Strategic Partnership with Novartis Canada to Relaunch Mayzent® for Multiple Sclerosis Patients in Canada
Teva Canada Limited (Teva Canada) is announcing a new commercialization and supply agreement with Novartis Pharmaceuticals Canada Inc. (Novartis Canada) for Mayzent® (siponimod), an innovative oral treatment for secondary progressive multiple sclerosis (SPMS) with active disease. Under the partnership, Teva Canada will assume exclusive responsibility for the promotion, distribution, and commercialization of Mayzent® in Canada.
About this update from Teva Pharmaceutical Industries Limited
[{"type":"text","content":"TORONTO, Feb. 2, 2026 /CNW/ - Teva Canada Limited (Teva Canada) is announcing a new commercialization and supply agreement with Novartis Pharmaceuticals Canada Inc. (Novartis Canada) for Mayzent® (siponimod), an innovative oral treatment for secondary progressive multiple sclerosis (SPMS) with active disease. Under the partnership, Teva Canada will assume exclusive responsibility for the promotion, distribution, and commercialization of Mayzent® in Canada.","length":465,"tagName":"p"},{"type":"image","alt":"Teva logo (CNW Group/Teva Canada)","displaySize":"","headline":null,"caption":"Teva logo (CNW Group/Teva Canada)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":201,"url":"https://media.zenfs.com/en/cnwgroup.com/43a7b9d6eee40008e8cbb48f0b99e2c9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/sZPQAnK8doTU6blw6LBbeQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1NDtjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/43a7b9d6eee40008e8cbb48f0b99e2c9","width":400,"height":201}},"href":"https://mma.prnewswire.com/media/2872792/Teva_Canada_Teva_Canada_Announces_Strategic_Partnership_with_Nov.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"This collaboration leverages Teva's established central nervous system (CNS) expertise and national commercial infrastructure, ensuring continued access to Mayzent® for Canadian patients and healthcare professionals. The agreement is designed to maximize the reach and impact of Mayzent®, building on Teva's established history with neurologists and MS specialists across the country.","length":392,"tagName":"p"},{"type":"text","content":""This is about more than a product - it's about people," said Fabien Paquette, General Manager, Teva Canada. "Through this partnership, we are reaffirming our dedication to the MS community and to patient-centred care. Teva Canada is proud to lead with purpose, ensuring access and support for those who need it most. We are all in for better health."","length":375,"tagName":"p"},{"type":"text","content":""This agreement reflects our shared responsibility to support people living with MS," said Dimitri Gitas, Country President, Novartis Canada "Through this partnership, we're strengthening support for Canadians living with multiple sclerosis and advancing bett...